Stocks and Investing Stocks and Investing
Wed, March 6, 2019
Tue, March 5, 2019
Mon, March 4, 2019

Matthew Harrison Maintained (SRPT) at Buy with Increased Target to $169 on, Mar 4th, 2019


Published on 2024-10-26 12:27:53 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Increased Target from $161 to $169 on, Mar 4th, 2019.

Matthew has made no other calls on SRPT in the last 4 months.



There are 3 other peers that have a rating on SRPT. Out of the 3 peers that are also analyzing SRPT, 0 agree with Matthew's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Matthew


  • Joel Beatty of "Citigroup" Maintained at Strong Buy with Increased Target to $201 on, Friday, March 1st, 2019
  • Alethia Young of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $231 on, Thursday, February 28th, 2019
  • Christopher Marai of "Nomura" Maintained at Strong Buy with Increased Target to $230 on, Thursday, February 28th, 2019

Contributing Sources